As reported, old DLBCL patients tended to accumulate genomic alterations, such as higher mutational frequencies of MYD88, PIM1, and CD79B, and changes in tumor immune microenvironment [3, 4, 6]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.